Close

Anti-C44H83NO9 T cell receptor (Vα24Jα18), pCDTCR1 (TCR-YC0215)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Type I natural killer T cells (iNKT) are a unique subpopulation of T cells with immunomodulatory properties. They are characterized by the expression of a semi invariant TCR based on a constant Vα rearrangement (Vα14Jα18 in mice and Vα24Jα18 in humans) paired with a limited number of Vβ chains (Vβ8.2, Vβ7, Vβ2 in mice and Vβ11 in humans), and are restricted by CD1d. This non classical antigen presenting molecule, as well as the other members of the non-polymorphic CD1 family, is specifically designed to bind hydrophobic ligands and specializes in the presentation of lipid based antigens from microbial or self origin, although it may also present other antigens such as peptides to various T cells subsets.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • C44H83NO9
  • Epitope
  • 1-O-(alpha-D-glucopyranosyl)-N-icosa-11,14-dienoylphytosphingosine
  • Format
  • Non-Modified TCR
  • Allele
  • Human CD1d
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • Vα24Jα18
  • Host Species
  • Human

Target

  • Introduction
  • A glycophytoceramide having an α-D-glucopyranosyl residue at the O-1 position and an icosa-11,14-dienoyl group attached to the nitrogen.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-C44H83NO9 T cell receptor (Vα24Jα18), pCDTCR1 (TCR-YC0215). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.